公开(公告)号：US20250066793A1

公开(公告)日：2025-02-27

申请号：US18724758

申请日：2022-12-28

Applicant: Development Center for Biotechnology

Inventor： Ying-Shuan LAILEE ,  Chia-Wei LIU ,  Chi-Tang WANG ,  Pei-Yi TSAI ,  Chung-Hsiun WU ,  King LAM ,  Wei-Ting SUN ,  Kai-Chien YANG ,  Hung-Jyun HUANG

IPC: C12N15/113 ,  A61P11/00

Abstract: Disclosed herein are novel single-stranded anti-sense oligonucleotides (ASOs) capable of reducing the transcription of thioredoxin domain containing protein 5 (TXNDC5) mRNA. Also disclosed is use of the single-stranded ASOs as disclosed herein for manufacturing medicaments suitable for treating a disease associated with upregulation of TXNDC5. Accordingly, a pharmaceutical composition comprising the disclosed ASO molecules is provided; as well as a method of treating a subject suffering from TXNDC5-mediated disease via administering to the subject the disclosed single-stranded ASO molecules.

公开(公告)号：US20220289759A1

公开(公告)日：2022-09-15

申请号：US17636116

申请日：2020-08-22

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shao-Zheng PENG ,  Chu-Bin LIAO ,  Hung-Jyun HUANG ,  Yuan-Ting CHO ,  Yi-Mei CHANG ,  Yu-Chih PAN

IPC: C07D495/04 ,  C07D519/00 ,  A61P35/00

Abstract: A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFRα, c-KIT and/or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and/or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and/or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.